RxDoctor Payments DataLook up a doctor →

Gavin Setzen, MD

Otolaryngology · Albany, NYNPI 1063419232

Payments from drug & device makers

$298,973in general payments, 2019–2025

Across 365 payments — averaging $819.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$196K
  • Aerin Medical Inc.$70K
  • Smith+Nephew$14K
  • Neurent Medical Limited$8K
  • Lilly USA, LLC$4K
  • Arrinex, Inc.$3K
  • plus $5K from 29 others

What the payments were for

  • Consulting fees$218,31090%
  • Speaking & faculty fees$3,7502%
  • Travel & lodging$13,4046%
  • Food & beverage$7,8233%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$298,973 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$212,772
Medicare patients
622
Services billed
8,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Budesonide122$29,364
Fluticasone Propionate434$10,950
Ipratropium Bromide208$7,701
Famotidine508$7,693
Mometasone Furoate49$6,147
Azelastine Hcl176$5,022
Omeprazole379$4,993
Epinephrine20$3,420
Montelukast Sodium247$2,551
Pantoprazole Sodium71$1,224
Albuterol Sulfate HfaAlbuterol Sulfate22$861
Cimetidine11$787
Levocetirizine Dihydrochloride58$774
Lansoprazole19$648
Ofloxacin11$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$16$3,42020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 otolaryngology providers in New York.

Other otolaryngology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →